dihexa human clinical trials status 2026 bpc-157 trial humans kpv bpc 157 tb500 human SCOPE dihexa human trials status 2026

Contents per vial: BPC-157 5mg + TB-500 (Thymosin Beta-4 fragment) 5mg

Thompson, C

Factors Influencing Duration in the Body Dosage: Higher doses may remain in circulation slightly longer, though the difference can be marginal

The inflammatory component of many chronic conditions deserves special attention

06 Administration Route: BPC 157 can be administered through various routes, including subcutaneous injection, oral consumption, or topical application

ONLY MIX WITH STERILE BACTERIOSTATIC WATER The purity and sterility of bacteriostatic water are essential to prevent contamination and to preserve the shelf-life of dissolved peptides